Abstract
BACKGROUND: This exploratory study investigates the therapeutic potential of Porcine Brain-Derived Peptide Mixture (PBDP) in Alzheimer's Disease (AD) by examining changes in quantitative electroencephalography (qEEG) parameters following treatment. METHODS: We analyzed qEEG data from 27 AD patients treated with 2-weeks of PBDP treatment and compared them to a control group of 20 patients at 2-month follow-up, all of whom were previously on donepezil therapy. RESULTS: EEG modifications were noted within two weeks of PBDP administration, including improvements in EEG patterns such as reduced Theta/Beta (4.437 ± 3.979 to 3.859 ± 3.587, p = 0.442), Theta/Alpha ratio (1.815 ± 1.637 to 1.578 ± 1.304, p < 0.05), and Delta/Alpha ratio (2.365 ± 2.471 to 2.105 ± 2.402, p < 0.05) across various brain regions, suggesting enhanced cortical activity. Post-intervention, 55% of patients showed caregiver-reported improvements in mood and daily activities. CONCLUSION: PBDP could serve as a viable therapeutic approach for managing AD, and qEEG could serve as a monitoring biomarker for acute drug effects, warranting further investigation into its long-term benefits and mechanistic pathways.